AP
Adam Pennycuick
University College London, Mount Vernon Hospital, Royal College of Physicians, St Bartholomew's Hospital, King's College London
Research areas: Medicine · Oncology · Lung Cancer Diagnosis and Treatment · Cancer Genomics and Diagnostics · Lung Cancer Research Studies
0000-0001-5836-0250
About
I am a computational oncologist based at University College London. I treat patients with lung cancer and use techniques from data science and mathematical modelling to understand cancer biology and improve cancer care.
Employment
-
University College, London Principle Research Fellow/Honorary Consultant2024 - Present
-
University College London NIHR Clinical Lecturer in Medical Oncology2021 - 2024
-
Mount Vernon Hospital Specialist Registrar in Medical Oncology2021 - 2021
-
St Bartholomew's Hospital Specialist Registrar in Medical Oncology2020 - 2021
-
University College London Wellcome Clinical PhD Fellowship2017 - 2020
-
University College London Academic Clinical Fellow2015 - 2017
-
King's College Hospital Academic Foundation Programme2013 - 2015
-
Stirling Dynamics Aerospace Engineer2006 - 2008
Education
-
University College London Doctor of Philosophy (PhD) - Wellcome Clinical Fellowship2017 - 2020
-
Royal College of Physicians Membership of the Royal College of Physicians (MRCP)2015 - 2016
-
King's College London Bachelor of Medicine, Bachelor of Surgery (MBBS)2009 - 2013
-
University of Warwick Undergraduate Masters in Mathematics and Physics (MPhys). First class honours.2001 - 2005
Projects & Funding
-
Parallelised Cancer Therapy based on Copy Number Targeting Academy of Medical Sciences2023 - 2024
-
Mechanisms of progression to invasive lung cancer: a systems biology approach Wellcome Trust Ltd2017 - 2020
Publications (37)
- From amplicon to antigen: a quantified transmission map that nominates multi-antigen antibody–drug-conjugate co-target sets across cancer types Save
- 114P Utility of longitudinal imaging data for lung cancer prediction Save
- Management of high-grade pre-invasive endobronchial lesions: To treat or not to treat? Save
- Toripalimab for extensive-stage small cell lung cancer: insights and future directions Save
- S128 Elucidating transcriptomic and functional differences between basal cells with a low and high mutational burden from tobacco smoke exposure in the normal human airway epithelium Save
- S135 Comparing changes in solid component diameter and mass for detecting invasive adenocarcinoma in sub-solid pulmonary nodules (SSNs): the SUMMIT study Save
- EP.07F.07 Role of Microbiome in the Outcome of the Preinvasive Lung Cancer Lesions Save
- Predicting histopathological features of aggressiveness in lung cancer using CT radiomics: a systematic review Save
- 166 Description of radiological growth patterns in screen-detected lung cancers: The ASCENT study cohort Save
- Abstract 5657: The intricate relationship between genomic damage and epidemiological lung cancer risk in ever-smokers Save
- Investigating chromosomal instability in long-term survivors with glioblastoma and grade 4 astrocytoma. Save
- Early human lung immune cell development and its role in epithelial cell fate. Save
- Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer. Save
- Cell-intrinsic differences between human airway epithelial cells from children and adults Save
- 331P Predicting outcomes following colorectal cancer resection: Using real-world data to empower adjuvant treatment decision making Save
- Abstract 3158: Defining the mechanisms that lead to mutational heterogeneity in the normal respiratory epithelium Save
- Chemoviz: an Interactive Web-based Tool for Time-series Analysis of Systemic Anti-cancer Therapy: Application to Analysis of Dose Modifications of CDK4/6 Inhibitors in Clinical Practice Save
- The CLIMB study: immune checkpoint inhibitor effects on lung airway mutational burden Save
- Power of Transcriptomics in Lung Biology Save
- BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma Save